Genome-wide scans have shown that common risk alleles for orofacial clefts (OFC) tend to be located in noncoding regulatory elements and cumulatively explain only part of the heritability of OFCs. Low-frequency variants may account for some of the "missing" heritability. Therefore, we scanned low-frequency variants located within putative craniofacial enhancers to identify novel OFC risk variants and implicate new regulatory elements in OFC pathogenesis. Analyses were performed in a multiethnic sample of 1,995 cases of cleft lip with or without cleft palate (CL/P), 221 cases with cleft palate (CP) only, and 1,576 unaffected controls. One hundred and nineteen putative craniofacial enhancers identified from ChIP-Seq studies in craniofacial tissues or cell lines contained multiple low-frequency (0.01-1%) variants, which we genotyped in participants using a custom Illumina panel. Two complementary statistical approaches, sequence kernel association test and combined multivariate and collapsing, were used to test association of the aggregated low-frequency variants across each enhancer region with CL/P and CP. We
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| INTRODUCTION
Orofacial clefts (OFCs) such as cleft lip with or without cleft palate (CL/P) and cleft palate alone (CP) are among the most common birth defects, worldwide, affecting roughly 1 in 700 births (Leslie & Marazita, 2013; Marazita, 2012) . CL/P and CP are hypothesized to have distinct etiologic risk factors due to epidemiological differences and the separate embryological origins of the upper lip and secondary palate. For example, approximately 70% of CL/P and 50% of CP cases are nonsyndromic, meaning they occur in the absence of other structural or cognitive abnormalities. Both nonsyndromic CL/P and CP are hypothesized to be genetically complex, with contributions from multiple genetic and environmental risk factors (Leslie & Marazita, 2013) .
Several genetic variants associated with OFCs have been identified through unbiased approaches, such as genome-wide association studies (GWASs; Beaty et al., 2010; Birnbaum et al., 2009; Grant et al., 2009; Ludwig et al., 2012; Ludwig et al., 2017; Mangold et al., 2010; Sun et al., 2015; Wolf et al., 2015) , which cumulatively explain about 20-30% (Ludwig et al., 2017) of the genetic variance in OFCs. These GWASs have typically interrogated common genetic variants-that is, those variants with minor allele frequencies (MAFs) greater than 1% in some human populations-due to limitations in statistical power for testing the individual effects of lower frequency variants. Altogether, results from these GWASs have suggested that many associated common variants fall in regulatory regions, which is consistent with findings from other complex diseases.
Other approaches, such as exome-wide association studies (Bureau et al., 2014; have investigated the role of low-frequency (i.e., MAF < 1%) coding variants on OFCs, implicating genes such as CDH1 (Bureau et al., 2014) , N4BP2, CDSN, PRTG, and AHRR . Moreover, candidate gene sequencing studies have investigated the effects of rare variants (Leslie & Murray, 2013) in genes such as BMP4 (Suzuki et al., 2009) , Chawa et al., 2014) , and ARHGAP29 (Leslie et al., 2012) .
Taken together, these studies show that rare variants, both coding and regulatory, may influence risk of OFCs. Given that identifying rare variant associations is challenging, especially in noncoding regions of the genome, we hypothesize that undiscovered lowfrequency variants affecting OFC risk may occur in noncoding regulatory elements, such as enhancers.
Distant-acting transcriptional enhancer regions are among the most abundant regulatory elements in the mammalian genome (Consortium, 2012; Visel, Rubin, & Pennacchio, 2009) , and, from an evolutionary perspective, they may be particularly important in the emergence of human craniofacial features (Prescott et al., 2015) .
These enhancer regions tend to activate gene expression in specific cell or tissue types, thus providing a mechanism for the fine-tuning expression during developmental processes. Previous work in mouse has shown that craniofacial enhancers orchestrate expression of genes during craniofacial development (Attanasio et al., 2013) . This leads to the question of whether genetic variation in craniofacial enhancer regions is associated with human craniofacial defects, including OFCs. Common variants in craniofacial enhancers have already been included as part of previously GWAS studies, albeit anonymously. Subsequent functional assays have demonstrated that associated SNPs at several loci disrupt the activity of their resident enhancers Lidral et al., 2015; Liu et al., 2017; Rahimov et al., 2008) . However, the possibility that low-frequency variants in these regions may impact risk of OFCs has not previously been explored. In this study we scanned 119 putative craniofacial enhancer regions that harbor lowfrequency genetic variants for genetic association with CL/P or CP in a multiethnic sample.
| METHODS

| Participant recruitment
The Pittsburgh Orofacial Clefts Study recruited a total of 11,727 participants from 11 countries across the Americas, Europe, and Asia , which consisted of nonsyndromic OFC cases, unaffected family members of cases, and unaffected controls.
For this study, we identified a subset of unrelated proband cases with OFCs (1,995 CL/P cases, and 221 CP cases) and 1,576 unrelated controls with no history of OFCs nor other craniofacial anomalies (Table 1) . Cases were recruited through craniofacial clinics or surgical mission trips. Where possible, healthy controls were recruited from the same populations.
| Editorial policies and ethical considerations
All participants provided informed consent to participate in this study.
All study protocols were approved by local Institutional Review Boards of participating sites, in addition to approvals at the University of Iowa and the University of Pittsburgh. Data analyzed in this study are publicly available at the National Center for Biotechnology Information database of Genotypes and Phenotypes (dbGaP) study "Center for Craniofacial and Dental Genetics (CCDG): Genetic of Orofacial Clefts and Related Phenotypes" (dbGap Study Accession: phs000774.
v2.p1).
| Genotyping, putative enhancer selection, and imputation
Genotyping was performed using the Illumina (San Diego) HumanCore+Exome array with 15,890 single nucleotide polymorphisms (SNPs) of custom content. The custom content included SNPs in putative craniofacial enhancer sequences identified by literature search of ChIP-Seq studies in craniofacial tissues or cell lines that were available in 2013, when the custom content was selected. These included (a) enhancers from the VISTA database with in vivo activity patterns annotated for "branchial arch", "nose", "facial mesenchyme", or "forebrain"; (b) putative and active enhancers identified from p300 ChIPSeq in mouse craniofacial tissue by Attanasio et al. (2013) ; and (c) craniofacial enhancers in the published literature. This field has rapidly expanded in recent years due to technological advances and epigenomic consortia such as ENCODE; therefore our selected enhancers should not be viewed as a comprehensive representation of craniofacial enhancers. Of 4,440 putative enhancer regions considered, 126 regions included multiple SNPs with MAF < 5%, and, therefore, were included in our statistical analysis. Note, enhancer regions that included only one SNP were excluded from the present analysis (in which we performed aggregate tests of multiple SNPs simultaneously) based on the assumptions of our statistical approach and because tests of common variants individually have already been reported as part of previous GWAS scans ( Leslie, Liu, et al., 2016) , and tests of individual low-frequency variants have insufficient statistical power. In total 804 SNPs across 126 putative craniofacial enhancer regions were analyzed (2-22 SNPs per enhancer; median of 5 SNPs). Sporadic missing genotypes were imputed using IMPUTE2 (Howie, Donnelly, & Marchini, 2009 ) software with the 1,000 Genomes Project (phase 3 release) as the reference panel. Imputation accuracy was assessed by masked variant analysis, which showed high quality imputation with mean concordance of 0.995. Most-likely genotypes were used in statistical analysis if the genotype probability was greater than .9, an arbitrary threshold set to ensure high confidence in imputed data.
| Statistical analysis
Genetic association of aggregated low-frequency variants across putative craniofacial enhancer regions was tested using two approaches: the combined multivariate and collapsing (CMC) method and the sequence kernel association test (SKAT). In brief, CMC is a burden test that collapses variants into a single score while assuming consistent direction of effect of minor alleles of all SNPs in an enhancer region (Li & Leal, 2008) . In contrast, SKAT allows minor alleles of SNPs to differ in the direction of effect (Wu et al., 2011) . These two approaches are complementary in that each has higher power in some circumstances, depending on whether or not minor alleles of SNPs with the enhancer region truly have effects in the same direction.
Tests of enhancer regions using CMC and SKAT were performed separately for CL/P and CP phenotypes as implemented in RVTESTS (Zhan, Hu, Li, Abecasis, & Liu, 2016) software. Two MAF ranges for low-frequency variants were considered. The principal analyses included putative enhancer regions with multiple low-frequency variants in the 0.01-1% range. For secondary analyses, this range was expanded include variants up to MAF of 5%. Because case-control analyses of CL/P and CP comprised different sets of participants, minor alleles were not observed for all variants in both analysis groups, and therefore not all enhancer regions were tested for each phenotype. Specifically, for the analyses of low-frequency variants with MAF < 1%, the CL/P scan tested 669 SNPs across 118 regions, whereas the CP scan tested 586 variants across 108 regions. For the analyses of variants with MAF <5%, the CL/P scan tested 804 SNPs across 126 regions, and the CP scan tested 719 SNPs across 115 regions.
To adjust for population structure, we included the first 18 principal components (PCs) of ancestry in our models as covariates. PCs of ancestry were derived from genome-wide data as previously described . Empirical significance for SKAT models was determined by 10,000 permutations. Associations with p-values less than the Bonferroni-corrected (for the number of regions tested) threshold were considered statistically significant, and p-values association via CMC or SKAT we performed SNP-wise tests for all variants in the enhancer region using logistic regression. SNPs showing individual effects were interrogated using HaploReg for chromatin state, protein binding, and eQTL annotations. Localization of enhancer activity was depicted using representative images from The VISTA Enhancer Browser (Visel, Minovitsky, Dubchak, & Pennacchio, 2007) .
| RESULTS
Low-frequency variants (MAF 0.01-1%) were tested in aggregate using two methods (CMC and SKAT) for putative craniofacial enhancer regions. Results are summarized in quantile-quantile plots shown in SNPs in the hs1717 enhancer, rs16924908 was the most significant (p-value = .02), and also shows chromatin state and histone marks consistent with its enhancer activity across multiple cell types, and is also not a recognized eQTL.
To expand the scope of the low-frequency variant scans, we reanalyzed putative enhancer regions while also considering more common variants of up to 5% MAF. Results for CMC and SKAT tests of the broader group low-frequency variants (MAF 0.01-5%) did not identify any additional significant associations, but did point to one new suggestive enhancer region (Supporting Information Figure S1 ).
However, inspection of allele intensity plots for SNPs in this suggestive enhancer region determined that the association may have been Figure S2 ). We interpret this suggestive association with great skepticism, and therefore discuss it no further.
| DISCUSSION
In this study we tested low-frequency variants in over 100 putative craniofacial enhancers across the genome for association with CL/P and CP. We identified an enhancer, mm60, near MITF and FOXP1 that was significantly associated with CP. Neither of these genes have been previously linked to OFCs, although both genes may be involved in craniofacial phenotypes.
MITF is a transcription factor involved in multiple cellular processes; notably, mutations in MITF cause Waardenburg syndrome, characterized by pigment abnormalities, hearing loss, telecanthus, and other symptoms including cleft lip that vary across patients. However, most, but not all (Pierpont, St Jacques, Seaver, & Erickson, 1995) , cases of Waardenburg syndrome presenting with clefts are due to mutations in another gene, PAX3, which has been further supported by a cleft palate murine model (Wu et al., 2008) . To the best of our knowledge, clefts have not been documented in Waardenburg syndrome cases caused by mutations in MITF.
FOXP1 is a transcription factor important for regulating gene expression during development. Mutations in FOXP1 are associated with developmental delay, intellectual disability, speech defects, and mild craniofacial abnormalities (Horn, 2012; Le Fevre et al., 2013; Myers et al., 2017) , including highly arched palate and hypertrophy of the alveolar ridges (Urreizti et al., 2018) . In mouse, expression patterns of Foxp1 in the first pharyngeal arch during development suggest that it may regulate jaw development, although expression was absent from the palatal shelf (Cesario, Almaidhan, & Jeong, 2016) . In addition, knockout mutants for Lhx6 and Lhx8, which bind to and repress transcription of FOX genes, show up-regulation of Foxp1 (as well as Foxp2, Foxc1, Foxd1, and Foxd2) and have major craniofacial defects including cleft palate (Cesario et al., 2015) . Taken together, these studies suggest that FOXP1 may be involved in regulating craniofacial development. Furthermore, if the chromosome 3p13 enhancer near FOXP1
regulates its expression, our results would point to a role of FOXP1 in risk of CP, although more work is necessary to replicate this association. We advocate that FOXP1 should be considered a high-priority target for future genetics studies of OFCs, and CP in particular, the cleft subtype for which fewer specific genes have been discovered.
In addition to the significant association observed for CP, we also identified an enhancer, hs1717, near FOXE1 that was suggestively associated with CL/P, but this relationship was not statistically significant after consideration of multiple testing. We observed similar effects in stratified analyses of both cleft lip alone and cleft lip and palate (results not shown). FOXE1 is a transcription factor expressed during palate formation and has been implicated in OFCs via multiple genetic approaches, including linkage analyses Moreno et al., 2009) , candidate gene sequencing studies (Moreno et al., 2009) , and GWAS (Leslie, Carlson, Shaffer, Butali, et al., 2017) .
The fact that we observe statistical evidence for an enhancer near this well-established OFC gene lends some credence to our study design, serving as an informal positive control.
Two rare variant tests were used, CMC and SKAT, because these approaches each have greater statistical power in some circumstances. CMC, which collapses the burden of low-frequency variants into a single score, operates under the assumption that all lowfrequency alleles in an enhancer region are deleterious, whereas SKAT can detect association with sets of variants when the low-frequency alleles differ in the directions of their effects. As we do not know the directions of effects ahead of time, CMC and SKAT approaches complement each other in our efforts to scan craniofacial enhancer regions across the genome for evidence of association with cleft phenotypes. This approach is commonly employed in rare variant analyses, and has proved useful in our study for detecting significant and suggestive associations.
This study was carried out in a multiethnic sample of participants, which included individuals of European, Asian, and South American ancestry. While spurious associations due to population structure were avoided by thoroughly adjusting for dimensions of genetic ancestry, it is possible that the rare-variant associations observed are driven primarily by one or more ethnic populations in the total sample, as allele frequencies, especially for rare variants, may differ across populations. Unfortunately, sample sizes were too small to perform rare variants tests separately by ancestry group. Larger and more homogeneous samples and sequencing approaches may be necessary to find any associations that went undetected in this analysis.
Additional studies will be needed to confirm the impact of the mm60 and hs1717 enhancer regions on OFCs, which poses a challenge in that the large sample sizes necessary for detecting low- 
